Utah Retirement Systems Raises Holdings in Becton Dickinson and Co (BDX)

Utah Retirement Systems grew its position in Becton Dickinson and Co (NYSE:BDX) by 0.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,343 shares of the medical instruments supplier’s stock after purchasing an additional 300 shares during the period. Utah Retirement Systems’ holdings in Becton Dickinson and were worth $12,879,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. increased its position in Becton Dickinson and by 1.3% in the 3rd quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock worth $4,966,582,000 after purchasing an additional 253,041 shares during the last quarter. FMR LLC boosted its stake in shares of Becton Dickinson and by 8.0% during the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after acquiring an additional 1,286,579 shares in the last quarter. Fundsmith Equity Fund L.P. bought a new stake in shares of Becton Dickinson and during the 2nd quarter worth about $894,775,000. Wells Fargo & Company MN boosted its stake in shares of Becton Dickinson and by 0.8% during the 3rd quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock worth $930,491,000 after acquiring an additional 27,188 shares in the last quarter. Finally, Putnam Investments LLC boosted its stake in shares of Becton Dickinson and by 0.5% during the 2nd quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock worth $841,690,000 after acquiring an additional 18,859 shares in the last quarter. 85.19% of the stock is currently owned by institutional investors.

In other Becton Dickinson and news, SVP Charles R. Bodner sold 2,080 shares of the company’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $245.83, for a total transaction of $511,326.40. Following the sale, the senior vice president now owns 4,497 shares of the company’s stock, valued at $1,105,497.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the transaction, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. Insiders have sold 81,795 shares of company stock valued at $19,571,318 over the last quarter. Company insiders own 1.00% of the company’s stock.

Several research firms have recently issued reports on BDX. UBS Group began coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price target for the company. Piper Jaffray Companies decreased their price target on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Citigroup decreased their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a research note on Tuesday, November 13th. Barclays set a $260.00 price target on Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday, November 8th. Finally, Wells Fargo & Co decreased their target price on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $254.20.

NYSE BDX traded down $7.64 during trading on Wednesday, reaching $244.92. 1,452,711 shares of the company’s stock were exchanged, compared to its average volume of 1,222,641. Becton Dickinson and Co has a fifty-two week low of $209.91 and a fifty-two week high of $265.87. The company has a market cap of $67.80 billion, a PE ratio of 22.25, a price-to-earnings-growth ratio of 1.75 and a beta of 1.21. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the company posted $2.40 earnings per share. The firm’s revenue for the quarter was up 39.0% compared to the same quarter last year. As a group, research analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 7th. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 1.26%. Becton Dickinson and’s dividend payout ratio is 27.25%.

TRADEMARK VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/05/utah-retirement-systems-raises-holdings-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply